Trial of Prasinezumab in Early-Stage Parkinson’s Disease,The New England Journal of Medicine

当前位置： X-MOL 学术 › N. Engl. J. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Trial of Prasinezumab in Early-Stage Parkinson’s Disease
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2022-08-04 , DOI: 10.1056/nejmoa2202867
Gennaro Pagano ₁ , Kirsten I Taylor ₁ , Judith Anzures-Cabrera ₁ , Maddalena Marchesi ₁ , Tanya Simuni ₁ , Kenneth Marek ₁ , Ronald B Postuma ₁ , Nicola Pavese ₁ , Fabrizio Stocchi ₁ , Jean-Philippe Azulay ₁ , Brit Mollenhauer ₁ , Lydia López-Manzanares ₁ , David S Russell ₁ , James T Boyd ₁ , Anthony P Nicholas ₁ , María R Luquin ₁ , Robert A Hauser ₁ , Thomas Gasser ₁ , Werner Poewe ₁ , Benedicte Ricci ₁ , Anne Boulay ₁ , Annamarie Vogt ₁ , Frank G Boess ₁ , Juergen Dukart ₁ , Giulia D'Urso ₁ , Rebecca Finch ₁ , Stefano Zanigni ₁ , Annabelle Monnet ₁ , Nathalie Pross ₁ , Andrea Hahn ₁ , Hanno Svoboda ₁ , Markus Britschgi ₁ , Florian Lipsmeier ₁ , Ekaterina Volkova-Volkmar ₁ , Michael Lindemann ₁ , Sebastian Dziadek ₁ , Štefan Holiga ₁ , Daria Rukina ₁ , Thomas Kustermann ₁ , Geoffrey A Kerchner ₁ , Paulo Fontoura ₁ , Daniel Umbricht ₁ , Rachelle Doody ₁ , Tania Nikolcheva ₁ , Azad Bonni ₁ , ,

Affiliation

From the Neuroscience and Rare Diseases, Discovery and Translational Area (G.P., K.I.T., A. Boulay, A.V., F.G.B., J.D., G.D., H.S., M.B., S.D., Š.H., T.K., G.A.K., D.U., A. Bonni), and Pharmaceutical Sciences (B.R.), Roche Pharma Research and Early Development (pRED), and Roche pRED Informatics (F.L., E.V.-V., M.L.), Roche Innovation Center Basel, and Product Development Neuroscience (S.Z., A.M., N. Pross, P.F., R.D., T.N.) and Product Development Safety (M.M., D.R.), F. Hoffmann-La Roche - all in Basel, Switzerland; University of Exeter Medical School, London (G.P.), Roche Products, Welwyn Garden City (J.A.-C., R.F.), and the Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N. Pavese) - all in the United Kingdom; the Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago (T.S.); Institute for Neurodegenerative Disorders, New Haven, CT (K.M., D.S.R.); the Department of Neurology, McGill University, and Montreal Neurological Institute, Montreal (R.B.P.); University San Raffaele Roma and the Institute for Research and Medical Care, IRCCS San Raffaele Pisana, Rome (F.S.); Centre Hospitalier de la Timone, Marseille, France (J.-P.A.); Paracelsus-Elena-Klinik, Kassel (B.M.), the Department of Neurology, University Medical Center Göttingen, Göttingen (B.M.), Hertie Institute for Clinical Brain Research, University of Tübingen, and the German Center for Neurodegenerative Diseases, Tübingen (T.G.), the Institute of Neurosciences and Medicine, Brain and Behavior, Research Center Jülich, Jülich (J.D.), the Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf (J.D.), and Excelya Germany, Freiburg (A.H.) - all in Germany; the Department of Neurology, University Hospital de La Princesa, Madrid (L.L.-M.), and University Clinic of Navarra, Pamplona (M.R.L.) - both in Spain; University of South Florida, Tampa (R.A.H.); University of Vermont Larner College of Medicine, Burlington (J.T.B.); University of Alabama Medical Center, Birmingham (A.P.N.); and the Department of Neurology, Innsbruck Medical University, Innsbruck, Austria (W.P.).

New England Journal of Medicine, Volume 387, Issue 5, Page 421-432, August 2022.

中文翻译：